|
Match
|
Document |
Document Title |
|
|
7354928 |
Small molecule inhibitors targeted at Bcl-2
The present invention relates to small molecule antagonists of Bcl-2 family proteins such as Bcl-2 and/or Bcl-X L . In particular, the present invention provides non-peptide cell permeable small...
|
|
|
7345046 |
Heteroaryl-fused pyrimidinyl compounds as anticancer agents
Heteroaryl-fused pyrimidinyl compounds, pharmaceutically acceptable salts, and prodrugs thereof; compositions that include a pharmaceutically acceptable carrier and one or more of the...
|
|
|
7268124 |
Geranylgeranyl pyrophosphate synthase inhibitors
The invention provides novel pyrophosphate synthase inhibitors of formula I as well as compositions comprising such inhibitors and methods for their use.
|
|
|
7205001 |
Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds
The invention relates to the use of arsenic compounds to treat a variety of neoplastic diseases. The present invention encompasses the administration to a mammal of arsenic in the form of a salt,...
|
|
|
7199111 |
Aqueous ifosfamide compositions for parenteral administration and a process for their preparations
The present invention provides aqueous Ifosfamide compositions and a process for their preparation, in which the compositions have a reduced toxicity over and above the concomitant use of the...
|
|
|
7166611 |
Pharmaceutical compositions having appetite suppressant activity
A pharmaceutical composition contains an extract obtainable from a plant of the genus Trichocaulon or Hoodia containing an appetite suppressant agent having the formula (1). A process for...
|
|
|
7163703 |
Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds
The invention relates to the use of arsenic compounds to treat a variety of neoplastic diseases. The present invention encompasses the administration to a mammal of arsenic in the form of a salt,...
|
|
|
7045495 |
Combination of bryostatin and paclitaxel for treating cancer
This invention provides methods for screening a modulating agent which when combined with antitumor therapeutic agent increases apoptosis in tumor cells. This invention also provides methods for...
|
|
|
6875451 |
Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds
The invention relates to the use of arsenic compounds to treat a variety of neoplastic diseases. The present invention encompasses the administration to a mammal of arsenic in the form of a salt,...
|
|
|
6770673 |
Therapeutic uses of arglabin in combination with other chemotherapy agents
Compositions and kits containing a first chemotherapeutic agent that includes arglabin or a derivative thereof and a second chemotherapeutic agent are described. The compositions and kits are...
|
|
|
6762174 |
Low molecular weight compounds administered together with anti-cancer agents to prevent or treat cancer and pharmaceutical compositions thereof
The present invention relates to peptide-like compounds, e.g. aminocarboxylic acid amide derivatives, and to methods of using same to stimulate cells of the immune system, bone marrow and other...
|
|
|
6737416 |
Phosphonic acid derivative having inhibitory activity against carboxypeptidase B
A compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof: wherein R 1 represents hydrogen atom, an alkyl group, a substituted alkyl group and...
|
|
|
6703400 |
Methods for treating multidrug resistance
Methods are provided for treating multidrug resistance in refractory tumor cells comprising administering (1) a P-glycoprotein inhibitor in conjunction with (2) an antineoplastic agent.
|
|
|
6649614 |
Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent for treatment of depression or anxiety
The present invention relates to the treatment of depression and/or anxiety by the administration of a combination of a specific class of NK-1 receptor antagonists and an antidepressant or...
|
|
|
6500811 |
Sulfonylaminophosphinic and sulfonylaminophosphonic acid derivatives, methods for their preparation and use
Compounds of the formula I are suitable for the production of pharmaceuticals for the prophylaxis and therapy of disorders in the course of which an increased activity of matrix-degrading...
|
|
|
6444638 |
Combinations of PKC inhibitors and therapeutic agents for treating cancers
This invention provides methods for screening a modulating agent which when combined with antitumor therapeutic agent increases apoptosis in tumor cells. This invention also provides methods for...
|
|
|
6319953 |
Treatment of depression and anxiety with fluoxetine and an NK-1 receptor antagonist
The present invention relates to the treatment or prevention of depression and/or anxiety by the administration of a combination of a specific class of NK-1 receptor antagonists and fluoxetine.
|
|
|
6204245 |
Treatment of narcolepsy with immunosuppressants
The invention provides compositions and methods for treatment of narcolepsy or isolated cataplexy. Such methods entail administering a therapeutically effective regime of at least one...
|
|
|
6200961 |
Concentrates of organophosphorous insecticides
A low volatile organic compound co-solvent system is disclosed for preparing emulsion concentrates of low melting organophosphorous insecticides wherein the bioefficacy of the insecticide active is...
|
|
|
6156749 |
Use of NK-1 receptor antagonists for treating movement disorders
The present invention provides the use of an orally active, long acting, CNS-penetrant NK-1 antagonist for the manufacture of a medicament for oral administration for the treatment or prevention of...
|
|
|
6133272 |
Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
Disclosed are nitrosated and/or nitrosylated phosphodiesterase inhibitors having the formula NO n N-PDE inhibitor where n is 1 or 2. The invention also provides compositions comprising such...
|
|
|
6117855 |
Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent
The present invention relates to the treatment or prevention of depression and/or anxiety by the administration of a combination of CNS-penetrant NK-1 receptor antagonists and an antidepressant or...
|
|
|
6114315 |
Use of NK-1 receptor antagonists for treating major depressive disorders with anxiety
The present invention provides methods for the treatment or prevention of major depressive disorder with anxiety without concomitant therapy with other anti-depressant or anti-anxiety agents which...
|
|
|
6096729 |
Use of NK-1 receptor antagonists for treating amnestic disorders
The present invention provides methods for the treatment or prevention of amnestic disorders which comprises oral administration of an orally active, long acting, CNS-penetrant NK-1 receptor...
|
|
|
6087348 |
Use of NK-1 receptor antagonists for treating stress disorders
The present invention provides the use of an orally active, long acting, CNS-penetrant NK-1 receptor antagonist for the manufacture of a medicament adapted for oral administration for the treatment...
|
|
|
6054445 |
Kappa agonist compounds pharmaceutical formulations and method of prevention and treatment of pruritis therewith
Compounds having kappa opioid agonist activity, compositions containing them and method of using them as analgesics and anti-pruritic agents are provided. The compound of formulae IIA, having the...
|
|
|
6028063 |
Kappa agonist compounds, pharmaceutical formulations and method of prevention and treatment of pruritus therewith
Compounds having kappa opioid agonist activity, compositions containing them and method of using them as analgesics and anti-pruritic agents are provided. The compounds of formula III having the...
|
|
|
6004955 |
Cyclic carbamates and isoxazolidines as IIb/IIIa antagonists
|
|
|
5958969 |
Benzo b!thiophene compounds, intermediates, formulations, and methods
This invention relates to the field of pharmaceutical and organic chemistry and provides benzothiophene compounds, intermediates, formulations, and methods.
|
|
|
5952315 |
Use of NK-1 receptor antagonists for treating bipolar disorders
The present invention provides methods for the treatment or prevention of bipolar disorder without concomitant therapy with other antidepressant or anti-anxiety agents which comprises oral...
|
|
|
5929054 |
Use of NK-1 receptor antagonists for treating sexual dysfunctions
The present invention provides a method for the treatment or prevention of sexual dysfunctions which comprises oral administration of an orally active, long acting, CNS-penetrant NK-1 receptor...
|
|
|
5925627 |
Use of NK-1 receptor antagonists for treating movement disorders
The present invention provides a method for the treatment or prevention of movement disorders using an orally active, long acting, CNS-penetrant NK-1 antagonist and pharmaceutical compositions...
|
|
|
5914351 |
Anti-viral aromatic hydrazones
Compounds of the formula ##STR1## wherein Q is a hydrazone derivative; R 1 is hydrogen, halogen, alkyl or alkoxy; R 2 is hydrogen, halogen, alkyl, alkoxy, alkenoxy, alkynyloxy, halomethyl,...
|
|
|
5902804 |
Pharmaceutical composition for inhibiting the growth of viruses and cancers
This invention is a pharmaceutical composition that inhibits the growth of cancers and tumors in mammals, particularly in human and warm blooded animals. The composition is also effective against...
|
|
|
5880111 |
Therapeutic derivations of diphosphonates
Novel chemotherapeutic agents having utility in treating infectious diseases such as periodontal disease, certain urinary tract infections, and infectious urinary tract stones, are obtained by...
|
|
|
5854227 |
Therapeutic derivatives of diphosphonates
Novel chemotherapeutic agents having utility in treating infectious diseases such as periodontal disease, certain urinary tract infections, infectious urinary tract stones, and bone cancer, are...
|
|
|
5741784 |
Benzopyran derivatives and their use
This invention relates to a compound represented by the formula: ##STR1## wherein B represents a hydrogen atom or a lower alkyl group; ring A represents a benzene ring which may have one or more...
|
|
|
5728687 |
Antitumour compositions containing taxane derivatives
Pharmaceutical compositions having therapeutic synergy comprising taxol or Taxotere or analogues thereof combined with at least one therapeutically useful substance for treating neoplastic diseases.
|
|
|
5716942 |
Treatment of migraine with morpholine tachykinin receptor antagonists
Substituted heterocycles of the general structural formula: ##STR1## are tachykinin receptor antagonists useful in the treatment of inflammatory diseases, pain or migraine, asthma, emesis and nausea.
|
|
|
5698541 |
2,4-diphosphonoglutaric acid derivatives, processes for their production and pharmaceutical agents containing these compounds
The invention concerns compounds of the general formula I ##STR1## in which R denotes a lower alkyl which can be substituted if desired by hydroxy, alkoxy, amino, dialkylamino, alkylmercapto,...
|
|
|
5676978 |
Methods of inhibiting undesirable cell growth using a combination of a cyclocreatine compound and a hyperplastic inhibitory agent
The present invention provides for the use of creatine compounds and hyperplastic inhibitory agents for prophylactic and/or therapeutic treatments of undesirable cell growth, e.g. tumors. The...
|
|
|
5652238 |
Esters of substituted-hydroxyacetyl piperazine phenyl oxazolidinones
A compound of structural Formula (I) or pharmaceutically acceptable salts thereof wherein: R is --C(O)--R 1 , --PO 3 or --P(O)(OH) 2 ; R 1 is C 1 -6 alkyl, --N(R 4 ) 2 , C 1 -6 alkyl-N(R 4 )...
|
|
|
5627173 |
Phosphonoacetic acid derivatives and their use for treating degenerative joint disorders
Phosphonoacetic acid derivatives and their use for treating degenerative joint disorders Compounds of the formula I ##STR1## are suitable for producing pharmaceuticals for the treatment and...
|
|
|
5622917 |
Substituted 1H--3-aryl-pyrrolidine-2,4-dione derivatives
The invention relates to new 1H-3-aryl-pyrrolidine-2,4-dione derivatives of the formula (I) ##STR1## in which A, B, X, Y and G have the meanings given in the description, to a plurality of...
|
|
|
5587375 |
Azepinone compounds useful in the inhibition of ACE and NEP
Compounds having the following formulae I and II, and pharmaceutically acceptable salts thereof, including dual inhibitors of ACE and NEP and selective ACE inhibitors: ##STR1## and wherein R, R 1 ,...
|
|
|
5580863 |
Benzopyran derivatives and their use
This invention relates to a compound represented by the formula: ##STR1## wherein B represents a hydrogen atom or a lower alkyl group; ring A represents a benzene ring which may have one or more...
|
|
|
5578623 |
Saccharin derivative proteolytic enzyme inhibitors
Compounds having the structural formula ##STR1## wherein L is O; L-R 1 is a leaving group, H-L-R 1 is the conjugate acid thereof and H-L-R 1 has a pK a value less than or equal to to 8; R...
|
|
|
5556841 |
Thiazine or thiomorpholine derivatives
This invention relates to the compounds of the formula [I] which are useful for the treatment of cataracts, and the synthetic intermediates of the formula [II], ##STR1## wherein R 1 is hydroxy...
|
|
|
5556614 |
Deodorant composition
This invention provides a deodorant composition comprising a phosphoric diester compound of the following formula or a pharmacologically acceptable salt thereof as an active deodorant ingredient....
|
|
|
5547952 |
3-oxo-1,4-benzothiazine derivatives
This invention relates to the compounds of the formula [I] which are useful for the treatment of cataracts, and the synthetic intermediates of the formula [II], ##STR1## wherein R 1 is hydroxy...
|